Traditional Chinese medicine composition for strengthening body resistance and benefiting lung as well as preparation method and application of traditional Chinese medicine composition

Through the effects of strengthening the lungs and nourishing the qi, spleen, kidney and essence filling, the symptoms of spontaneous sweating, head and body dysfunction, depression, and difficulty breathing in patients with new crowns have been solved, which significantly improves the sense of health and happiness, and provides a Safe and suitable for long-term use of traditional Chinese medicine treatment plans.

CN118924852AActive Publication Date: 2024-11-12GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410068309.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-04-11
Filing Date
2024-01-17
Publication Date
2024-11-12
Estimated Expiration
2044-01-17

AI Technical Summary

Technical Problem

Patients with COVID-19 have poor treatment effects on long-term use of Western medicine, and are prone to trigger drug resistance and toxic side effects, and lack effective Chinese medicine compositions for treatment.

Method used

Develop a traditional Chinese medicine composition that can strengthen the lungs, including Codonopsis pilosula, Astragalus, Tangerine peel, Poria cocos, fried lentils, fried malt, Morinda monsoon, Ophiopogon japonicus, Schisandra chinensis and roasted licorice. Through the effects of invigorating qi and strengthening the spleen, nourishing the kidney and filling the essence, Improve clinical symptoms of lung and spleen deficiency and kidney qi deficiency.

Benefits of technology

Significantly improves the symptoms of spontaneous sweating, heavy head and body, depression, and difficulty breathing in patients with new crown, and improves their sense of health and happiness. Due to the characteristics of the same origin of medicine and food, it is suitable for long-term drinking and is highly safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for strengthening body resistance and benefiting lung as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by mass: 10-20 parts of codonopsis pilosula, 10-20 parts of astragalus membranaceus, 3-15 parts of pericarpium citri reticulatae, 10-25 parts of poria cocos, 10-40 parts of fried hyacinth beans, 10-30 parts of fried malt, 5-20 parts of morinda officinalis, 5-20 parts of radix ophiopogonis, 5-15 parts of schisandra chinensis and 5-15 parts of honey-fried licorice root. The traditional Chinese medicine composition has the effects of replenishing qi to invigorate the spleen and tonifying the kidney to replenish essence, can well improve the symptoms of spontaneous perspiration, head and body tiredness, depression and dyspnea of patients with lung-spleen deficiency and kidney-qi deficiency syndrome new crown growth, and remarkably improves happiness and health feeling.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for strengthening the body and benefiting the lungs, its preparation method, and its application. Background Technology

[0003] According to the World Health Organization, prolonged COVID-19 refers to the presence of symptoms at least three months after infection with the novel coronavirus, with symptoms and effects lasting for at least two months and unexplained by other diagnoses. Based on conservative estimates, prolonged COVID-19 accounts for 10% of all COVID-19 infections. With 651 million recorded cases worldwide, at least 65 million people globally are in a prolonged COVID-19 state. This number is likely higher due to numerous unreported cases. Prolonged COVID-19 symptoms severely impact people's health, well-being, and livelihoods.

[0004] Symptoms of prolonged COVID-19 can be categorized into three types: residual symptoms after recovery, organ dysfunction persisting after recovery, and new symptoms in asymptomatic or mild cases. It can involve multiple systems, including the circulatory, respiratory, urinary, digestive, endocrine, nervous, and mental systems, and includes a variety of symptoms such as fatigue, chest tightness, shortness of breath, chest pain, palpitations, cognitive impairment (brain fog), sleep disturbances, gastrointestinal symptoms, anxiety, and depression. The immune response after COVID-19 infection is initially strong but then weakens. Initially, pro-inflammatory responses dominate, followed by a chronic immunosuppressive phase, with persistent inflammation, immunosuppression, and catabolism syndrome (PICS) predominating during the recovery period. Studies show that persistent fatigue is the most common symptom of prolonged COVID-19, accounting for 53.1%-72.0%. Fatigue symptoms can occur in both COVID-19 patients who have been hospitalized in the ICU and those with mild symptoms, often lasting for more than 6 months. Persistent fatigue, along with symptoms such as weakness, sweating, shortness of breath, and loss of appetite, severely impacts patients' work and daily life.

[0005] Prolonged COVID-19 is characterized by its long course, high recurrence rate, and lengthy treatment period. Long-term use of Western medicine not only fails to provide satisfactory results but also easily leads to drug resistance, increases the incidence of adverse reactions, and may even damage the body's immune function, thus presenting certain limitations. Traditional Chinese medicine (TCM), with its multi-target efficacy and fewer side effects, has played an important role in the treatment of COVID-19 infection. Currently, there is still a lack of effective TCM compositions for treating prolonged COVID-19; therefore, it is necessary to develop such a TCM composition. Summary of the Invention

[0006] The first objective of this invention is to provide a traditional Chinese medicine composition that strengthens the body and benefits the lungs; the second objective of this invention is to provide a method for preparing the traditional Chinese medicine composition; and the third objective of this invention is to provide an application of the traditional Chinese medicine composition.

[0007] According to a first aspect of the present invention, a traditional Chinese medicine composition for strengthening the body and benefiting the lungs is provided, wherein the raw materials comprise, by weight, the following: 10-20 parts of Codonopsis pilosula, 10-20 parts of Astragalus membranaceus, 3-15 parts of Citrus reticulata peel, 10-25 parts of Poria cocos, 10-40 parts of stir-fried Dolichos lablab, 10-30 parts of stir-fried Hordeum vulgare, 5-20 parts of Morinda officinalis, 5-20 parts of Ophiopogon japonicus, 5-15 parts of Schisandra chinensis, and 5-15 parts of prepared Glycyrrhiza uralensis.

[0008] This invention suggests that the symptoms of COVID-19 patients, such as fatigue, weakness, chest tightness, shortness of breath, sweating, cough, sputum, soreness of the lower back and knees, bloating, poor appetite, loose or sticky stools, pale tongue, white and greasy tongue coating, and weak pulse, are considered to be symptoms of lung and spleen deficiency and kidney qi insufficiency. Therefore, based on its pathogenesis and clinical manifestations, this invention proposes a formula.

[0009] In this formula, Codonopsis pilosula and Astragalus membranaceus enter the spleen and lung meridians, tonifying the middle energizer, replenishing qi, strengthening the lungs and tonifying the defensive qi, and consolidating the exterior to stop sweating; together they serve as the principal herbs. Poria cocos strengthens the spleen, eliminates dampness, calms the mind and soothes the nerves; stir-fried Dolichos lablab tonifies qi, harmonizes the middle energizer, and resolves dampness; Citrus reticulata peel regulates qi, strengthens the spleen, dries dampness, and resolves phlegm. The combination of Poria cocos, stir-fried Dolichos lablab, and Citrus reticulata peel ensures that the spleen is strengthened without causing stagnation, and that dampness is resolved without depleting yin. Morinda officinalis tonifies the kidneys, assists yang, dispels wind, and eliminates dampness. Poria cocos, stir-fried Dolichos lablab, Citrus reticulata peel, and Morinda officinalis tonify both the spleen and kidneys; together they serve as the assistant herbs. Stir-fried Hordeum vulgare promotes digestion and strengthens the stomach, while also soothing the liver and relieving depression. Combined with Codonopsis pilosula and Astragalus membranaceus, it facilitates the absorption of their tonifying effects without causing bloating. Ophiopogon japonicus and Schisandra chinensis prevent the other herbs from being too warming and drying. Schisandra chinensis also helps to prevent the leakage of qi and fluids and replenish the depletion of qi and yin; together they serve as the adjuvant herbs. Prepared Glycyrrhiza uralensis strengthens the spleen, replenishes qi, and harmonizes the other herbs; it serves as the guiding herb. The combined effects of these herbs are to invigorate qi and strengthen the spleen, as well as to nourish the kidneys and replenish essence, which can significantly improve the clinical symptoms of long-term COVID-19 patients.

[0010] The raw materials for this formula come from the following sources:

[0011] Codonopsis pilosula: The dried root of Codonopsis pilosula (Franch.) Nannf., Codonopsis pilosula Nannf. var. modesta (Nannf.) L. Shen, or Codonopsis tangshen Oliv., all belonging to the Campanulaceae family. It enters the Spleen and Lung meridians. It is sweet and neutral in nature.

[0012] Astragalus: The dried root of *Astragalus membranaceus* (Fisch.) Bge. var. *mongholicus* (Bge.) Hsiao or *Astragalus membranaceus* (Fisch.) Bge. (Fabaceae family). It enters the Lung and Spleen meridians. It is sweet and warm in nature.

[0013] Dried tangerine peel: The dried, mature peel of the citrus fruit and its cultivated varieties, belonging to the Rutaceae family. It is bitter and pungent, and warm in nature. It enters the spleen and lung meridians.

[0014] Poria: The dried sclerotium of the fungus *Poria cocos* (Schw.) Wolf (family Polyporaceae). It enters the heart, lung, spleen, and kidney meridians. It is sweet, bland, and neutral in nature.

[0015] Stir-fried Hyacinth Beans: The white seeds of the hyacinth bean plant (Lycium chinense). Enters the spleen and stomach meridians. Sweet and neutral in nature.

[0016] Roasted malt: Obtained by germinating and drying the mature fruit of barley (Hordeum vulgare L.), a plant belonging to the Poaceae family. It enters the spleen and stomach meridians. It is sweet and neutral in nature.

[0017] Morinda officinalis: The dried root of Morinda officinalis How, a plant in the Rubiaceae family. It enters the kidney and liver meridians. It is sweet, pungent, and slightly warm.

[0018] Ophiopogon japonicus: The tuberous root of Ophiopogon japonicus, a plant in the Liliaceae family. It enters the lung, stomach, and heart meridians. It is sweet and slightly bitter, and cold in nature.

[0019] Schisandra chinensis: The dried, ripe fruit of Schisandra chinensis (Turcz.) Baill. or Schisandra sphenanthera Rehd. et Wils., both belonging to the Magnoliaceae family. It enters the Lung, Heart, and Kidney meridians. It is sour, sweet, and warm in nature.

[0020] Prepared licorice root: The dried root of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat., or Glycyrrhiza glabra L. (all belonging to the legume family). It enters the heart, lung, spleen, and stomach meridians. It is sweet and neutral in nature.

[0021] In some embodiments, the raw material composition by weight includes: 15 parts Codonopsis pilosula, 15 parts Astragalus membranaceus, 10 parts Citrus reticulata peel, 15 parts Poria cocos, 15 parts stir-fried Dolichos lablab, 20 parts stir-fried Hordeum vulgare, 10 parts Morinda officinalis, 10 parts Ophiopogon japonicus, 5 parts Schisandra chinensis, and 10 parts prepared Glycyrrhiza uralensis.

[0022] In some embodiments, the dosage form of the traditional Chinese medicine composition is an oral solution, powder, or granule.

[0023] In some implementations, pharmaceutically acceptable excipients are also included.

[0024] In some embodiments, the excipient is at least one selected from the following: sustained-release agent, excipient, filler, binder, wetting agent, disintegrant, absorption promoter, adsorbent carrier, surfactant, and lubricant.

[0025] According to a second aspect of the present invention, a method for preparing the above-mentioned lung-strengthening and tonifying traditional Chinese medicine composition is provided. When the dosage form of the traditional Chinese medicine composition is an oral solution, the preparation method includes the following steps:

[0026] Soak the raw materials in 8-12 times their weight of water for 20-40 minutes, then heat to boiling and maintain a gentle boil for 1-2 hours. Filter, and repeat the decoction process 1-2 times on the residue. Combine the filtrates to obtain the final product. The oral solution is further packaged after cooling, making it easy to carry and distribute.

[0027] According to a third aspect of the present invention, a method for preparing the above-mentioned lung-tonifying and tonifying traditional Chinese medicine composition is provided, wherein when the dosage form of the traditional Chinese medicine composition is a powder, the preparation method includes the following steps:

[0028] Crush or chop each raw material separately, then pass the crushed or chopped raw materials through 10-mesh and 50-mesh sieves respectively. Continue to crush or chop the coarse particles that cannot pass through the 10-mesh sieve, and take the powder that is between the 10-mesh and 50-mesh sieves. Then mix the powders of each raw material according to the formula, put them into a packaging bag, and seal it.

[0029] According to a fourth aspect of the present invention, the use of the above-described tonifying and lung-nourishing traditional Chinese medicine composition in the preparation of a medicament for treating COVID-19 is provided.

[0030] In some implementations, the syndrome of prolonged COVID-19 is characterized by deficiency of both lung and spleen, and insufficiency of kidney qi. Specifically, the symptoms of prolonged COVID-19 include fatigue, weakness, chest tightness, shortness of breath, sweating, cough, phlegm, soreness and weakness of the lower back and knees, bloating, poor appetite, loose or sticky stools, pale tongue, white and greasy tongue coating, and weak pulse.

[0031] According to a fifth aspect of the present invention, the application of the above-described tonifying and lung-benefiting traditional Chinese medicine composition in the preparation of a medicinal and edible substitute tea is provided.

[0032] In the traditional Chinese medicine composition of the present invention, Codonopsis pilosula, Astragalus membranaceus, Morinda officinalis, Ophiopogon japonicus, and Schisandra chinensis are traditional Chinese medicinal materials listed in the "List of Items that can be Used in Health Foods", while Citrus reticulata peel, Poria cocos, stir-fried Dolichos lablab, stir-fried Hordeum vulgare, and prepared Glycyrrhiza uralensis are traditional Chinese medicinal materials listed in the "List of Items that are Both Foods and Medicines". The raw materials have the characteristics of being both food and medicine and being safe to use, and can be used to prepare a substitute tea that is both food and medicine.

[0033] The preparation method of the medicinal and edible substitute tea of ​​the present invention includes the following steps: Codonopsis pilosula, Astragalus membranaceus, Citrus reticulata peel, Poria cocos, stir-fried Dolichos lablab, stir-fried Hordeum vulgare, Morinda officinalis, Ophiopogon japonicus, Schisandra chinensis, and Glycyrrhiza uralensis are dried to a moisture content of <3.0%, impurities and inferior raw materials are removed, and after ultraviolet sterilization, each raw material is weighed according to the raw material ratio, and mixed evenly to obtain the product.

[0034] The resulting medicinal and edible substitute tea is packaged in a gauze tea bag and brewed with 100mL of warm water before use.

[0035] This invention's medicinal and edible tea can invigorate qi and strengthen the spleen, nourish the kidneys and replenish essence without being warming or drying; it can soothe the liver and regulate qi, promote digestion and stimulate appetite without causing stagnation; it can strengthen the spleen, resolve dampness and phlegm without depleting yin, making it suitable for long-term consumption. This medicinal and edible tea has excellent therapeutic effects on symptoms of COVID-19 such as spontaneous sweating, heaviness in the head and body, depression, and difficulty breathing.

[0036] Compared with the prior art, the beneficial effects of the present invention include:

[0037] (1) This invention adopts the method of syndrome differentiation and treatment in traditional Chinese medicine. By invigorating qi and strengthening the spleen, and tonifying the kidney and replenishing essence, it can effectively improve the clinical symptoms of long-term COVID-19 patients with deficiency of both lung and spleen and insufficient kidney qi, such as spontaneous sweating, heaviness in the head and body, depression, and difficulty breathing. This invention does not use any antitussive or chest-relieving drugs, but can improve respiratory symptoms such as difficulty breathing, cough, and expectoration in long-term COVID-19 patients by selecting and combining drugs that invigorate qi and strengthen the spleen, and tonify the kidney and resolve phlegm.

[0038] (2) This invention addresses the characteristics of prolonged COVID-19 illness, high recurrence rate, and long treatment cycles. The selected Chinese medicinal materials are either those listed in the "List of Items that can be Used in Health Foods" or those listed in the "List of Items that are Both Food and Medicine." The raw materials have the characteristics of being both food and medicine and are safe to use. The resulting Chinese medicine composition is suitable for long-term consumption. The Chinese medicine composition of this invention is exquisitely formulated, which can invigorate qi and strengthen the spleen, replenish kidney essence without being warming or drying, soothe the liver and regulate qi, promote digestion and stimulate appetite without causing stagnation, strengthen the spleen and resolve dampness, resolve phlegm and stop cough without depleting yin, so that the qi, blood, yin and yang of the lungs, spleen and kidneys are restored to a balanced state, thereby effectively improving various symptoms of prolonged COVID-19.

[0039] (3) Astragalus can replenish qi and strengthen the exterior, and it can also invigorate qi. Although a large dose of Astragalus can replenish the original qi more quickly, its qi-invigorating effect can easily cause patients to experience symptoms of internal heat such as insomnia, irritability, oral ulcers, and sore throat. Patients are also prone to coughing due to qi reversal. Therefore, the Chinese medicine composition of this invention uses only a small dose of Astragalus. By combining it with Codonopsis pilosula, prepared licorice root, and Morinda officinalis, it can replenish both the congenital and acquired spleen and kidneys, so that the effect of replenishing the lungs, spleen, and kidneys can be maximized. Furthermore, by combining it with Schisandra chinensis and Ophiopogon japonicus, it can replenish without causing dryness. By combining it with roasted malt, tangerine peel, Poria cocos, and roasted hyacinth bean, it can replenish without causing stagnation. This can effectively avoid symptoms such as insomnia, irritability, oral ulcers, sore throat, and coughing.

[0040] (4) The traditional Chinese medicine composition of the present invention can significantly improve symptoms such as spontaneous sweating and heaviness in the head and body in patients with long-term COVID-19; improve the scores of physical function, overall health and self-report of health changes in the SF-36 health status questionnaire, the utility index score and health status score of the European Five-Dimensional Health Scale EQ-5D-5L, the depression score of the Hospital Anxiety and Depression Scale (HADS), and the score of the dyspnea rating scale (mMRC scale), and significantly improve the health and well-being of patients with long-term COVID-19. Detailed Implementation

[0041] The present invention will be further described in detail below with reference to specific embodiments. It is worth noting that the following embodiments are only for better explaining the content of the present invention and do not limit the scope of protection of the present invention. Process steps not disclosed in the embodiments are prior art. Unless otherwise specified, all raw materials are commercially available.

[0042] Example 1

[0043] The oral solution for strengthening the lungs and benefiting the body in this embodiment is composed of the following ingredients: Codonopsis pilosula 15g, Astragalus membranaceus 15g, Citrus reticulata peel 10g, Poria cocos 15g, stir-fried Dolichos lablab 15g, stir-fried Hordeum vulgare 20g, Morinda officinalis 10g, Ophiopogon japonicus 10g, Schisandra chinensis 5g, and prepared Glycyrrhiza uralensis 10g.

[0044] Its preparation method includes the following steps:

[0045] Add all ingredients to 1500ml of water and decoct for 1.5 hours until reduced to 300-400ml to obtain a lung-strengthening oral solution.

[0046] Example 2

[0047] The lung-strengthening oral solution of this embodiment is composed of the following ingredients: Codonopsis pilosula 15g, Astragalus membranaceus 15g, Citrus reticulata peel 10g, Poria cocos 15g, stir-fried Dolichos lablab 15g, stir-fried Hordeum vulgare 15g, Morinda officinalis 10g, Ophiopogon japonicus 10g, Schisandra chinensis 5g, and prepared Glycyrrhiza uralensis 10g.

[0048] Its preparation method includes the following steps:

[0049] Add all ingredients to 1500ml of water and decoct for 1.5 hours until reduced to 300-400ml to obtain a lung-strengthening oral solution.

[0050] Example 3

[0051] The oral solution for strengthening the lungs and benefiting the body in this embodiment is composed of the following ingredients: Codonopsis pilosula 15g, Astragalus membranaceus 15g, Citrus reticulata peel 10g, Poria cocos 15g, stir-fried Dolichos lablab 15g, stir-fried Hordeum vulgare 20g, Morinda officinalis 10g, Ophiopogon japonicus 10g, Schisandra chinensis 5g, and prepared Glycyrrhiza uralensis 10g.

[0052] Its preparation method includes the following steps:

[0053] (1) Soak the raw materials in 10 times their weight of water for 30 minutes, then heat to boiling and keep simmering for 1 hour. After separation, obtain the first decoction and the dregs. Take the dregs obtained after the first decoction, add water equivalent to 8 times the total weight of the raw materials, heat to boiling and keep simmering for 1 hour. After separation, obtain the second decoction and the dregs. Combine the first decoction and the second decoction to obtain the lung-strengthening oral solution.

[0054] (2) Cool the obtained Fuzheng Yifei oral solution and then dispense it into smaller containers.

[0055] Example 4

[0056] The lung-strengthening powder of this embodiment is composed of the following ingredients: Codonopsis pilosula 15g, Astragalus membranaceus 15g, Citrus reticulata peel 10g, Poria cocos 15g, stir-fried Dolichos lablab 15g, stir-fried Hordeum vulgare 20g, Morinda officinalis 10g, Ophiopogon japonicus 10g, Schisandra chinensis 5g, and prepared Glycyrrhiza uralensis 10g.

[0057] Its preparation method includes the following steps:

[0058] (1) Take Codonopsis pilosula, crush it, and pass it through a 10-mesh and a 50-mesh sieve at the same time. Continue to crush the coarse particles that cannot pass through the 10-mesh sieve, and take the powder that is between the 10-mesh and 50-mesh sieves.

[0059] (2) Following the method in step (1), pulverize Astragalus membranaceus, Citrus reticulata peel, Poria cocos, stir-fried Dolichos lablab, stir-fried Hordeum vulgare, Morinda officinalis, Ophiopogon japonicus, Schisandra chinensis, and prepared Glycyrrhiza uralensis into powder respectively;

[0060] (3) Mix all the raw material powders evenly, pack them into a sealed bag, and seal it. When taking it, dissolve it in 150mL of warm water.

[0061] Example 5

[0062] The oral solution for strengthening the lungs and benefiting the body in this embodiment is composed of the following ingredients: Codonopsis pilosula 10g, Astragalus membranaceus 10g, Citrus reticulata peel 3g, Poria cocos 10g, stir-fried Dolichos lablab 10g, stir-fried Hordeum vulgare 10g, Morinda officinalis 5g, Ophiopogon japonicus 5g, Schisandra chinensis 7g, and Glycyrrhiza uralensis 5g.

[0063] Its preparation method is similar to that of Example 1.

[0064] Example 6

[0065] The oral solution for strengthening the lungs and benefiting the body in this embodiment is composed of the following ingredients: Codonopsis pilosula 20g, Astragalus membranaceus 20g, Citrus reticulata peel 15g, Poria cocos 25g, stir-fried Dolichos lablab 40g, stir-fried Hordeum vulgare 30g, Morinda officinalis 20g, Ophiopogon japonicus 20g, Schisandra chinensis 15g, and prepared Glycyrrhiza uralensis 15g.

[0066] Its preparation method is similar to that of Example 1.

[0067] To illustrate the therapeutic effect of the traditional Chinese medicine composition of the present invention on COVID-19, a clinical trial was conducted using the lung-strengthening oral solution prepared in Example 1.

[0068] I. Relevant Standards

[0069] (I) Diagnostic criteria

[0070] 1. Western medicine disease diagnosis

[0071] Referring to the diagnostic criteria in the "Expert Consensus on the Diagnosis and Treatment of COVID-19 with Traditional Chinese Medicine" published by the China Association of Traditional Chinese Medicine:

[0072] (1) Diagnosed with novel coronavirus infection for more than 3 months according to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial Version 10);

[0073] (2) The relevant symptoms or signs have persisted for more than 2 months;

[0074] (3) For symptoms or signs caused by other underlying diseases, a detailed medical history should be taken into account to identify and rule them out.

[0075] If all three criteria above are met, a diagnosis of chronic COVID-19 can be made.

[0076] 2. Diagnostic criteria for syndromes in Traditional Chinese Medicine

[0077] Lung and spleen deficiency syndrome with insufficient kidney qi: fatigue, weakness, chest tightness, shortness of breath, sweating, cough, phlegm, soreness and weakness of the lower back and knees, abdominal distension, poor appetite, loose or sticky stools, pale tongue, white and greasy tongue coating, and weak pulse.

[0078] (II) Inclusion Criteria

[0079] 1. Those diagnosed with chronic COVID-19 based on the diagnostic criteria of the "Expert Consensus on the Diagnosis and Treatment of Chronic COVID-19 with Traditional Chinese Medicine" published by the China Association of Traditional Chinese Medicine;

[0080] 2. Conforms to the syndrome of lung and spleen deficiency and kidney qi insufficiency;

[0081] 3. Treatment with the lung-strengthening oral solution from Example 1.

[0082] (III) Exclusion Criteria

[0083] 1. Individuals with impaired consciousness, cognitive impairment, or mental disorders who are unable to cooperate in completing the questionnaire and other information collection;

[0084] 2. Known allergy to traditional Chinese medicine;

[0085] 3. Those who do not cooperate with taking traditional Chinese medicine;

[0086] 4. Pregnant women;

[0087] 5. Individuals with significant organ dysfunction, such as those suffering from acute myocardial infarction, respiratory failure, or liver failure;

[0088] 6. Individuals who have recently participated in other experimental studies;

[0089] 7. Other cases that are not suitable for inclusion.

[0090] II. Research Design

[0091] Retrospective, observational, and self-controlled study designs.

[0092] III. Source of Cases

[0093] The cases were from a long-term COVID-19 patient who visited Guangdong Provincial Hospital of Traditional Chinese Medicine between April and July 2023.

[0094] IV. Observation Indicators and Time Points

[0095] (1) General information: gender, age, date of birth, occupation, height, weight, etc.;

[0096] (2) COVID-19 related medical history: onset time, hospitalization time, treatment measures, discharge time, residual symptoms after discharge and related treatment, etc.;

[0097] (3) Other disease-related information: past medical history, whether the past disease has worsened since this discharge, and respiratory infection status after discharge;

[0098] (4) Traditional Chinese Medicine Syndrome Scoring Scale;

[0099] (5) Respiratory function related scales: Dyspnea Rating Scale (mMRC scale);

[0100] (6) Quality of life: Health status questionnaire SF-36, European five-dimensional health scale EQ-5D-5L, fatigue severity scale FSS;

[0101] (7) Psychological state: Hospital-administered Anxiety and Depression Scale (HADS);

[0102] (8) Blood routine test.

[0103] V. Traditional Chinese Medicine Treatment Plan:

[0104] The lung-strengthening oral solution of Example 1 was used. One dose was 300-400ml, one dose per day, divided into two administrations; the course of treatment was 7 days.

[0105] Patients receiving TCM syndrome differentiation and treatment were included in the Fuzheng Yifei formula group.

[0106] Patients receiving treatment based on traditional Chinese medicine syndrome differentiation should, in principle, not take other Chinese medicines.

[0107] VI. Statistical Methods

[0108] All data were entered into an Excel database and analyzed using SPSS 22.0 software. Quantitative data were expressed as mean ± standard deviation, and comparisons between groups were performed using t-tests or ANOVA. Data from multiple time points were analyzed using repeated measures methods. Non-normally distributed data were analyzed using nonparametric tests. Categorical variables were expressed as number of cases and percentages, and comparisons between groups were performed using χ² tests or exact tests. Univariate correlations were analyzed using Pearson analysis. Multivariate logistic regression analysis was used to predict prognostic risk factors. A p-value < 0.05 was considered statistically significant.

[0109] This study employed intention-to-treat (ITT) analysis, which means that the results of a clinical trial include follow-up data from all patients. The advantage of ITT analysis is that it is unbiased; every participant, regardless of whether they are followed up to the observation endpoint, will participate in the final statistical analysis according to their initial grouping, thus preserving comparability between groups.

[0110] VII. Test Results

[0111] The number of follow-up cases is shown in Table 1:

[0112] Table 1. Number of cases followed up

[0113]

[0114] As shown in Table 1, there were 55 cases in the Fuzheng Yifei formula group, of which 33 cases had only baseline records and 22 cases had both baseline records and 7-day follow-up records.

[0115] The patient's baseline information is shown in Table 2:

[0116] Table 2 Baseline data of patients

[0117]

[0118] Note: The group treated with the Fuzheng Yifei formula consisted of 55 patients. In the table, there were 25 males and 29 females, totaling 54 patients (male + female = 54). One case was missing. The medical history of the patients in the Fuzheng Yifei formula group during their recovery period is shown in Table 3.

[0119] Table 3 Patients' medical history during the recovery period

[0120]

[0121]

[0122] Note: The group with the Fuzheng Yifei formula consisted of 55 cases. The missing values ​​for different symptoms were inconsistent. Please see the table for details.

[0123] As can be seen from Table 3, the three most common symptoms during the recovery period are fatigue, weakness, and shortness of breath, while diarrhea, constipation, and abdominal distension are relatively rare.

[0124] Table 4 shows the before-and-after comparison of the TCM syndrome scores of the patients after taking the medication:

[0125] Table 4 Analysis of changes in TCM syndrome scores

[0126]

[0127]

[0128] Note: The group with the Fuzheng Yifei formula consisted of 55 cases, with 1 case missing from the table.

[0129] As shown in Table 4, the differences in the scores of spontaneous sweating and heaviness in the head and body before and after treatment were statistically significant (P < 0.05). This indicates that the traditional Chinese medicine composition of the present invention can significantly improve the symptoms of spontaneous sweating and heaviness in the head and body in patients with chronic COVID-19.

[0130] Table 5 shows the analysis of changes in the SF-36 health status questionnaire scores of patients after taking medication:

[0131] Table 5. Analysis of changes in SF-36 health status questionnaire scores.

[0132]

[0133]

[0134] Note: The group with the Fuzheng Yifei formula consisted of 55 cases, with 1 case missing from the table.

[0135] As shown in Table 5, there were statistically significant differences in physical function, overall health perception, and self-reported health changes scores before and after treatment (P < 0.05). This indicates that the traditional Chinese medicine composition of the present invention can significantly improve physical function, overall health perception, and self-reported health changes in COVID-19 patients.

[0136] Table 6 shows the changes in the European Five-Dimensional Health Inventory (EQ-5D-5L) scores of patients after taking the medication:

[0137] Table 6. European Five-Dimensional Health Scale (EQ-5D-5L)

[0138]

[0139] Note: The group with the Fuzheng Yifei formula consisted of 55 cases, with 1 case missing from the table.

[0140] As shown in Table 6, the differences in the utility index score and health status score of the European Five-Dimensional Health Inventory (EQ-5D-5L) before and after medication were statistically significant (P < 0.05). This indicates that the traditional Chinese medicine composition of the present invention can significantly improve the health status of COVID-19 patients.

[0141] Table 7 shows the analysis of changes in the Fatigue Severity Scale (FSS) scores after patients took medication:

[0142] Table 7. Analysis of changes in Fatigue Severity Scale (FSS) scores.

[0143]

[0144]

[0145] Note: The group with the Fuzheng Yifei formula consisted of 55 cases, with 1 case missing from the table.

[0146] As shown in Table 7, there was no statistically significant difference in the Fatigue Severity Scale (FSS) scores before and after treatment.

[0147] Table 8 shows the changes in the hospital's Anxiety and Depression Scale (HADS) scores after the patients took the medication:

[0148] Table 8. Analysis of changes in scores on the Hospital Anxiety and Depression Scale

[0149]

[0150] Note: The group with the Fuzheng Yifei formula consisted of 55 cases, with 1 case missing from the table.

[0151] As shown in Table 8, the difference in depression scores before and after treatment was statistically significant (P < 0.05). This indicates that the traditional Chinese medicine composition of the present invention can significantly improve the depressive symptoms of COVID-19 patients.

[0152] The changes in the patient's dyspnea score on the mMRC scale after medication administration are shown in Table 9.

[0153] Table 9. Analysis of changes in scores on the Dyspnea Rating Scale

[0154]

[0155] Note: According to Table 1, there were 55 cases in the Fuzheng Yifei formula group, of which 22 cases had baseline data and 7-day follow-up records. Therefore, in Table 9, the total number of cases at baseline is 33 / 61.1% = 54 cases, with 1 case missing, and the total number of cases on day 7 is 19 / 86.4% = 22 cases.

[0156] As shown in Table 9, the difference in the dyspnea score before and after treatment was statistically significant (P < 0.05). This indicates that the traditional Chinese medicine composition of the present invention can significantly improve dyspnea symptoms in patients with chronic COVID-19.

[0157] In summary, after 7 days of treatment, patients with long-term COVID-19 showed significant improvement in symptoms such as spontaneous sweating and heaviness in the head and body, with statistically significant differences. Statistically significant differences were also observed before and after treatment in the following assessments: SF-36 physical function, overall health perception, self-reported health changes, EQ-5D-5L utility index score, health status score, Hospital Anxiety and Depression Scale (HADS) depression score, and mMRC dyspnea score. These findings indicate that the traditional Chinese medicine composition of this invention can significantly improve symptoms such as spontaneous sweating, heaviness in the head and body, depression, and dyspnea in patients with long-term COVID-19, and significantly enhance their sense of health and well-being.

[0158] The above descriptions are merely some specific embodiments of the present invention. For those skilled in the art, various modifications and improvements can be made without departing from the inventive concept of the present invention, and all such modifications and improvements fall within the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for strengthening the body and benefiting the lungs, characterized in that: The raw material composition, measured by mass, includes: 10-20 parts of Codonopsis pilosula, 10-20 parts of Astragalus membranaceus, 3-15 parts of dried tangerine peel, 10-25 parts of Poria cocos, 10-40 parts of fried lentils, 10-30 parts of fried malt, 5-20 parts of Morinda officinalis, 5-20 parts of Ophiopogon japonicus, 5-15 parts of Schisandra chinensis, and 5-15 parts of roasted Licorice root.

2. The Chinese medicine composition for strengthening the body and benefiting the lungs according to claim 1, characterized in that: The raw material composition, measured by mass, includes: 15 parts of Codonopsis pilosula, 15 parts of Astragalus membranaceus, 10 parts of dried tangerine peel, 15 parts of Poria cocos, 15 parts of stir-fried lentils, 20 parts of stir-fried malt, 10 parts of Morinda officinalis, 10 parts of Ophiopogon japonicus, 5 parts of Schisandra chinensis, and 10 parts of roasted Licorice root.

3. The Chinese medicine composition for strengthening the body and benefiting the lungs according to claim 1 or 2, characterized in that: The dosage form of the Chinese medicine composition is oral solution, powder or granule.

4. The Chinese medicine composition for strengthening the body and benefiting the lungs according to claim 1 or 2, characterized in that: Pharmaceutically acceptable excipients are also included.

5. The Chinese medicine composition for strengthening the body and benefiting the lungs according to claim 4, characterized in that: The auxiliary material is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, an adsorption carrier, a surfactant, and a lubricant.

6. The method for preparing the Chinese medicine composition for strengthening the body and benefiting the lungs according to any one of claims 1 to 5, characterized in that: When the dosage form of the Chinese medicine composition is an oral solution, the preparation method thereof comprises the following steps: The raw material is added into 8-12 times of the weight of water and soaked for 20-40 minutes, then heated to boiling, kept slightly boiling for 1-2 hours, filtered, and the filter residue is repeatedly decocted 1-2 times, and the filtrate is combined to obtain the product.

7. The method for preparing the Chinese medicine composition for strengthening the body and benefiting the lungs according to any one of claims 1 to 5, characterized in that: When the dosage form of the Chinese medicine composition is a powder, the preparation method thereof comprises the following steps: The raw materials are crushed or chopped separately, and then the crushed or chopped raw materials are passed through 10-mesh and 50-mesh sieves respectively, and the coarse particles that cannot pass through the 10-mesh sieve are further crushed or chopped, and the powder between the 10-mesh sieve and the 50-mesh sieve is taken, and then the raw material powders are mixed according to the proportion, put into the packaging bag, and sealed.

8. Use of the traditional Chinese medicine composition for strengthening the body and benefiting the lungs as described in any one of claims 1-5 in the preparation of medicines for treating COVID-19.

9. The use according to claim 8, characterized in that: The syndrome of COVID-19 is deficiency of both lung and spleen and insufficient kidney qi.

10. Use of the Chinese medicinal composition for strengthening the body and benefiting the lungs according to any one of claims 1 to 5 in preparing a substitute tea for both medicinal and edible purposes.

Citation Information

Patent Citations

  • Chinese patent medicine granules tonifying spleen and benefiting lung and preparation method thereof

    CN107669859A

  • Epidemic prevention traditional Chinese medicine composition, and preparation method and application thereof

    CN111214566A